Gradientech publishes Annual Report for 2023

Gradientech AB's Annual Report for 2023 has been published and is now available on the company's website.

The Annual Report for 2023 is attached to this press release and can also be downloaded at gradientech.se

For further information, please contact:

Sara Thorslund, CEO
Tel: + 46 763 29 35 80
sara.thorslund@gradientech.se

Urban Adolfsson, CFO
Tel: + 46 708 20 72 09
urban.adolfsson@gradientech.se

About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.